Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Non-Current Liabilities (2022 - 2025)

Historic Total Non-Current Liabilities for Heron Therapeutics (HRTX) over the last 4 years, with Q3 2025 value amounting to $229.4 million.

  • Heron Therapeutics' Total Non-Current Liabilities fell 1196.36% to $229.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $229.4 million, marking a year-over-year decrease of 1196.36%. This contributed to the annual value of $266.2 million for FY2024, which is 388.12% up from last year.
  • Latest data reveals that Heron Therapeutics reported Total Non-Current Liabilities of $229.4 million as of Q3 2025, which was down 1196.36% from $258.6 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Total Non-Current Liabilities ranged from a high of $266.2 million in Q4 2024 and a low of $229.4 million during Q3 2025
  • Its 4-year average for Total Non-Current Liabilities is $251.5 million, with a median of $255.8 million in 2024.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 833.64% in 2024, then plummeted by 1196.36% in 2025.
  • Heron Therapeutics' Total Non-Current Liabilities (Quarter) stood at $237.1 million in 2022, then increased by 8.05% to $256.2 million in 2023, then increased by 3.88% to $266.2 million in 2024, then decreased by 13.83% to $229.4 million in 2025.
  • Its Total Non-Current Liabilities stands at $229.4 million for Q3 2025, versus $258.6 million for Q2 2025 and $263.5 million for Q1 2025.